Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution

Summary

Phase I Study to evaluate safety and tolerability of PRO-230 (atropine sulphate 0.05%) ophthalmic solution through evaluation of incidence of non-expected adverse events (AE), photophobia, pupillary diameter, incidence of expected adverse events, and best near corrected visual acuity (BNCVA)

Timeline

Start

2023-02-01

Primary completion

2023-03-31

Completion

2023-04-24

Drugs

Indications